

Appropriate prescribing of Direct Oral Anticoagulants (DOACs) - Summary Clinical Guideline

(Table 1. From the full guideline of dosing for licensed indications).

See full guideline for drug interactions, renal/hepatic impairment, monitoring, extremes of body weight, pregnancy, missed doses, administration factors

	Renal Function (CrCl)	Apixaban	Dabigatran	Edoxaban	Rivaroxaban
Prevention of stroke and systemic embolism in patients with NVAF	>95ml/min 50-95ml/min	Preferred first line. 5mg twice daily. Reduce dose to 2.5mg twice daily if patient has 2 or more of the following characteristics: Cr ≥133mmol/L Age ≥80years Weight ≤ 60kg	150mg twice daily 110mg twice daily if age ≥ 80 years or receiving concomitant verapamil Consider 110mg twice daily if bleeding risk high, GI risk, moderate renal impairment or age between 75-80 years	Not advisable 60mg once daily 30mg once daily if weight ≤ 60kg or receiving concomitant ciclosporin, dronedarone, erythromycin, ketoconazole.	20mg once daily. Take with food.
	30-49ml/min 15 – 29ml/min <15ml/min or undergoing	2.5mg twice daily Not recommended	Not recommended	30mg once daily Not recommended	15mg once daily. Take with food. Not recommended
Treatment of DVT and/or PE	dialysis ≥50ml/min	10mg twice daily for 7 days followed by 5mg twice daily as maintenance.	150 mg twice daily following at least 5 days parenteral anticoagulant treatment. 110mg twice daily if age ≥ 80 years or concomitant verapamil. Consider 110 mg twice daily if thrombotic risk low, but bleeding risk high: e.g. 75-80 years, CrCL 30-50mL/min or at other increased risk of bleeding (e.g. GI). Following at least 5 days parenteral anticoagulant.	Least preferred 60mg once daily following at least 5 days of parenteral anticoagulant treatment. 30mg once daily if weight ≤ 60kg or receiving concomitant ciclosporin, dronedarone, erythromycin, ketoconazole. Following at least 5 days of parenteral anticoagulant treatment.	15mg twice daily for 21 days then 20mg once daily as maintenance. Take with food.

	30-49ml/min 15-29ml/min	No dose adjustment. 10mg twice daily for 7 days followed by 5mg twice daily as maintenance. Use with caution.	Not recommended.	Least preferred 30mg once daily. Following at least 5 days of parenteral anticoagulant treatment.	15mg twice daily for 21 days then 20mg once daily as maintenance. Reduce maintenance dose to 15mg once daily if bleeding risk outweighs risk for recurrent DVT or PE. Take with food.
	<15ml/min or undergoing dialysis	Not recommended		Not recommended	Not recommended
Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE	≥50ml/min	2.5mg twice daily Following completion of 6 months at treatment dose.	150mg twice daily. 110mg twice daily if age ≥ 80y or concomitant verapamil	60mg once daily. 30mg once daily if weight ≤ 60kg or receiving concomitant ciclosporin, dronedarone, erythromycin, ketoconazole.	10mg once daily (consider 20mg once daily if high risk of recurrent DVT/PE e.g. complicated co-morbidities or if developed recurrent DVT or PE
	30-49ml/min	No dose adjustment necessary. Use with caution.	Consider 110 mg twice daily if thrombotic risk low, but bleeding risk high: e.g. 75-80 years, CrCL 30- 50mL/min or at other increased risk of bleeding (e.g. GI)	30mg once daily	on extended prevention with 10mg once daily) Following completion of 6 months at treatment dose. Take with food.
	15-29ml/min		Not recommended		
	<15ml/min or undergoing dialysis	Not recommended		Not recommended	Not recommended
Prevention of atherothrombotic events in patients:	≥50ml/min	Not licensed	Not licensed	Not licensed	2.5mg twice daily (when administered with aspirin alone or with aspirin plus clopidogrel)
- After ACS with elevated cardiac biomarkers OR					Extension of treatment beyond 12 months should be done on an
With CAD or symptomatic PAD at high risk of ischaemic events	30-49ml/min				individual patient basis as experience up to 24 months is limited
	15-29ml/min	-			No dose adjustment. Use with caution.
	<15ml/min or undergoing dialysis				Not recommended.

References: British National Formulary, Summary of Product Characteristics

Prevention of thrombo-	≥50ml/min	2.5 mg twice daily. Initial dose should be taken 12 to	SEE FULL GUIDELINE FOR DOSING	Not licensed	10mg once daily. Take with food. Initial dose taken 6-10 hours
embolism after total hip		24 hours after surgery.	INIONIVATION		after surgery provided
(35 days) or knee (14 days)		Duration of treatment: THR = 32-38 days TKR = 10-14 days			haemostasis has been established. Duration of treatment:
replacement in adults	30-49ml/min	- TKK - 10 14 days	SEE FULL GUIDELINE FOR DOSING INFORMATION		THR = 5 weeks TKR = 2 weeks
	15-29ml/min	No dose adjustment. Use with caution.	Not recommended		No dose adjustment. Use with caution.
	<15ml/min or undergoing	Not recommended			Not recommended.
	dialysis				

^{*}See full clinical guideline for apixaban prescribing in haemodialysis patients